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We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with
multiple myeloma in ﬁrst relapse after front-line treatment with VMP or VTP. Reappearance of CRAB
symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common
patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16
(11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line
induction (21.4 vs. 14.4 months, P¼0.037), in patients achieving CR (28.3 vs. 14.8 months; P¼0.04), and
in patients without aggressive relapse (28.6 vs. 7.6 months; P¼0.0007).
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple myeloma (MM) is the second most common hema-
tologic malignancy and presents primarily in elderly patients, with
a median age at manifestation of approximately 72 years in Europe
[1,2]. The number of older patients with this disease is expected toLtd. This is an open access article u
0443235.
versity Hospital Doctor Peset,
þ34 96 162 2312.
ia).rise over time as a consequence of the increased life expectancy of
the normal population. In recent years, the introduction of novel
agents such as thalidomide, lenalidomide, and the proteasome
inhibitor bortezomib has changed the management of elderly
myeloma patients and extended overall survival (OS) times in all
age categories supporting the use of modern anti-myeloma ther-
apy independent of age [3,4].
Despite this improvement in OS, MM remains incurable and the
majority of patients ultimately relapses and require further ther-
apy. Thus, knowledge of relapse patterns and management of re-
lapsed disease is a critical aspect of MM treatment and annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sequence or combination of post relapse therapeutic strategies
remains unclear, and information is needed on the efﬁcacy of each
treatment, especially in the second-line setting. In this regard,
previous reports focused on patients relapsing after conventional
chemotherapy or autologous stem cell transplantation [6–8], and
such data on elderly patients in the era of novel therapies is
limited.
With the aim of understanding whether exposure to novel
agents based induction affected the efﬁcacy of subsequent therapy
we have conducted a post hoc subgroup analysis of 145 patients
with MM in ﬁrst symptomatic relapse previously included in the
GEM2005MAS65 Spanish trial. Front-line therapy in this trial
consisted of bortezomib, melphalan, and prednisone (VMP) or
bortezomib, thalidomide, and prednisone (VTP).2. Methods
The Spanish GEM05MAS65 trial lasted from March, 2006 to
October, 2008 and included 260 patients from 63 Spanish centers.
At study entry, every patient was aged 65 years or older and had
newly diagnosed, untreated, symptomatic, measurable MM. These
patients had received a homogeneous induction treatment con-
sisting either in bortezomib, melphalan, and prednisone (VMP) or
bortezomib, thalidomide, and prednisone (VTP). Design of the
study and treatment arms have been extensively described else-
where [9–11]. Brieﬂy, patients were upfront randomized to receive
induction with 6 cycles of VMP or VTP. One hundred and seventy
eight patients completed the six induction cycles and were ran-
domly assigned to maintenance therapy with bortezomib plus
prednisone (VP, n¼87) or bortezomib plus thalidomide (VT, n¼91)
[9–11].
As of December 31st, 2013, 164 patients of the GEM05MAS65
trial had suffered disease relapse or progression. One hundred and
forty-ﬁve (88%) received second line therapy and form the basis of
this study. Nineteen (12%) patients were excluded due to asymp-
tomatic relapse at time of analysis (11 patients), no data at relapse
(6 patients) and early death after relapse without receiving sec-
ond-line therapy (2 patients) (Fig. 1).Relapse/pro
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Fig. 1. Flow diagram of2.1. Deﬁnitions
Response to salvage therapy and clinical relapses were eval-
uated according to the International Myeloma Working Group
(IMWG) criteria, but near complete response (nCR) category, as
deﬁned by disappearance of monoclonal protein at routine elec-
trophoresis but positive immunoﬁxation, was added [12]. Biolo-
gical relapse was deﬁned as progressive, asymptomatic increase in
M-component and clinical relapse was deﬁned as evidence of or-
gan dysfunction and reappearance of CRAB features. For the pur-
pose of this article, aggressive relapse was considered when the
patient presented extramedullary plasmacytomas, plasma cell
leukemia or severe renal failure requiring hemodialysis at time of
relapse.
2.2. Statistical analysis
The proportions of patients with a given set of characteristics
were compared by the chi-square test or by the Fisher exact test.
The chi-square and Fisher exact tests were also used, as appro-
priate, to compare overall response, complete response (CR), and
nCR between both groups. The duration of PFS was calculated from
the start of the second line treatment to new disease progression,
death from any cause, or reference date (December 31, 2013). Pa-
tients who were alive and discontinued the study without evi-
dence of disease progression were censored at the last evaluation
for assessment of PFS. OS was calculated as the time from start of
the second line treatment until death from any cause, or censored
at the last reference date. PFS, and OS were plotted according to
the Kaplan–Meier product-limit method with comparisons made
by the log-rank test. All patients were followed until death or re-
ference date (December 31, 2013). All statistical analyses were
performed with version 3.0.1 of R software (The R Project for
Statistical Computing) [13].3. Results
3.1. Characteristics of patients at relapse
Median age at time of relapse in the overall series was 74.4gression
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Table 1
Type of front-line induction regimen and characteristics of patients at ﬁrst relapse.
Charac teristic No. (%) Median (range) VMP Induction n¼67 (%) VTP Induction n¼78 (%)
Male 69 (47.6) 33 (49.3) 36 (46.2)
Age (years) 74.4 (66 –87.5) 74.5 (66–87.5) 74.3 (66.3–87.2)
M protein
IgG 80 (57.6) 38 (60.3) 42 (55.3)
IgA 43 (30.9) 20 (31.7) 23 (30.3)
Light chain 16 (11.5) 5 (7.9) 11 (14.5)
ISS stage
1 35 (29.7) 15 (28.3) 20 (30.8)
2 46 (39) 22 (41.5) 24 (36.9)
3 37 (31.3) 16 (30.2) 21 (32.3)
Creatinine42 (mg/dl) 13 (9) 3 (4.5) 10 (13)
Hemoglobin (mg/dl) 11.4 (6.5–15.3) 11.5 (6.7–14.7) 11.4 (6.5–15.3)
Calcium410.5 (mg/dl) 6 (4.2) 3 (4.5) 3 (3.9)
Plasma cell leukemia 4 (2.8) 2 (3) 2 (2.6)
Extramedullary plasmacytoma 27 (18.6) 12 (17.9) 15 (19.2)
Hemodialysis 1 (0.7) 0 (0) 1 (1.3)
Type of relapse
Biological 31 (21) 16 (24) 15 (19)
Clinical 82 (57) 37 (55) 45 (58)
Aggressive 32 (22) 14 (21) 18 (23)
Interval diagnosis-relapse (months) 16.4 (0.03–67.5) 19.2 (0–67.5) 15.0 (0–65.2)
VMP: Bortezomib, Melphalan, and Prednisone; VTP: Bortezomib, Melphalan, and Thalidomide.
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Median time between diagnosis and relapse was 16.4 months
(range, 3–67.5). Overall, 67 patients had received front-line ther-
apy with VMP and 78 received induction with VTP. Clinical and
laboratory characteristics at time of relapse were well balanced
between both groups of patients (Table 1). Twenty-ﬁve and 26
patients in VMP received maintenance with VP or VT, respectively.
In the VTP induction group maintenance consisted on VP in 26
patients and VT in 30 patients. Finally, 38 patients did not receive
any type of maintenance because they progressed before to be
randomized to maintenance or due to front-line induction-asso-
ciated side effects.
3.2. Characteristics of relapse
Reappearance of CRAB symptoms was the most frequently type
of relapse and it was observed in 82 (56.6%) patients while 31
(21.4%) patients presented a previous phase of biological relapse
before developing MM-related symptoms. Median (range) time
between biological and clinical relapse was 5.1 (2–24) months.
Thirty-two (22%) patients presented some type of aggressive re-
lapse. No association was found between the pattern of relapse
(aggressive vs. non-aggressive) and the type of induction therapy
administered at the time of diagnosis.
3.2.1. Treatment for relapse
Median time between disease relapse or progression and in-
itiation of therapy was 17 days in the VMP (range, 0–1755) and 12Table 2
Type of treatment administered at ﬁrst relapse.
Type of therapy Total (%) Front-line treatment
VMP
n¼67 (%)
Bortezomib-based 25 (17.3) 11 (16.4)
Lenalidomide-based 78 (53.8) 39 (58.2)
Conventional chemotherapy 34 (23.5) 12 (17.9)
Supportive care 8 (5.5) 5 (7.5)
VMP: Bortezomib, Melphalan, and Prednisone; VTP: Bortezomib, Melphalan, and Thaliddays (range, 0–711) in the VTP group of patients (P non sig-
niﬁcant). Relapse therapy was not predeﬁned in the GEM2005-
MAS65 protocol. Lenalidomide-based combinations were the most
commonly regimens administered (78 patients: 57.2% and 50% in
the VMP and VTP arms, respectively). Retreatment with bortezo-
mib-containing regimens were administered as rescue therapy in
25 (17.3%) patients, eleven (16.4%) in the VMP group and 14 (18%)
in the VTP groups. Thirty-four (23.5%) patients received conven-
tional chemotherapy-containing regimens (12 (8.2%) in the VMP
group and 22 (15.2%) in the VTP group); ﬁnally, 8 (5.5%) patients
received supportive care as the only therapy for myeloma after
relapse (5 in the VMP group and 3 in the VTP group). Table 2
shows the therapy regimens used to treat ﬁrst relapse.
3.3. Response according to induction therapy
One hundred and thirty-one patients who relapsed were eva-
luable for response to rescue therapy while 14 patients died
shortly after relapse and could not be evaluated. According to the
front-line regimen administered, no differences in the rate of
partial response or better was observed in patients receiving VMP
(37 patients, 55.2%) or VTP (38 patients, 48.7%). Investigator-re-
ported best responses to second line therapies are summarized in
Table 3.
3.4. Response according to maintenance therapy
When considering the responses observed according to thePost induction maintenance
VTP VP VT None
n¼78 (%) n¼51 (%) n¼56 (%) n¼38 (%)
14 (18) 8 (15.7) 10 (17.9) 7 (18.4)
39 (50) 28 (54.9) 37 (66.1) 13 (34.2)
22 (28.2) 12 (23.5) 7 (12.5) 15 (39.5)
3 (3.8) 3 (5.9) 2 (3.6) 3 (7.9)
omide; VP: Bortezomib and Prednisone; VT: Bortezomib and Thalidomide.
Table 3
Best response to rescue therapy.
VMP Inductionn¼67 (%) VTP Inductionn¼78 (%)
Bz-based no. (%) Len-based no. (%) CC no. (%) SC no. (%) Bz-based no. (%) Len-based no. (%) CC no. (%) SC no. (%)
CR 0(0) 7(18.4) 0 0 2 (14.3) 6(15.4) 1 (4.8) 0
nCR 3(27.3) 11(28.9) 0 0 2 (14.3) 9 (23.1) 4 (19) 0
PR 3(27.3) 9(23.7) 4 (40) 0 1 (7.1) 10 (25.6) 3(14.3) 0
SD 3 (27.3) 6 (15.8) 1 (10) 0 4 (28.6) 4 (10.3) 5 (23.8) 0
NE 0 (0) 1 (2.6) 2 (16.7) 2 (40) 0 (0) 0 (0) 1 (4.5) 1 (33.3)
PD 2 (18.2) 3 (7.9) 4 (40) 3 (60) 4 (28.6) 6 (15.4) 6 (28.6) 2 (100)
ORR 6 (54.5) 27 (69.2) 4 (40) 0 5 (35.7) 25 (64.1) 8 (38.1) 0
VMP: Bortezomib, Melphalan, and Prednisone; VTP: Bortezomib, Melphalan, and Thalidomide; CC: Conventional chemotherapy; SC: Supportive care; CR: Complete re-
sponse; nCR: Near complete response, PR: Partial response; SD: Stable disease; NE: Not evaluable; PD: Progressive disease; ORR: Overall response rate (comprises partial
response or better).
Fig. 2. Post relapse progression-free survival according to front-line treatment
(A) and (B) progression-free survival depending on the type of therapy adminis-
tered at relapse.
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better was observed in 28 (56%) patients receiving VP and in 32
(58%) patients receiving VT.
3.5. Response according to rescue therapy
Partial response or better was achieved in 52 (67%) patients
after lenalidomide-based combinations and in 11 (44%) patients
receiving bortezomib-based therapy (P¼0.04). Twelve (35%) out of
the 34 patients receiving conventional chemotherapy achieved at
least partial response. Complete responses were observed in 13
(25%) and in 2 (18%) patients receiving lenalidomide-based and
bortezomib-based therapy, respectively.
3.6. Progression-free survival
The median follow-up from the time of disease relapse or
progression was 14.3 months and 136 patients (94%) have pro-
gressed or died after relapse. The median PFS after relapse in the
overall series was 8.84 (95% conﬁdence interval [CI]: 6.37–11.53)
months and it was 9.92 (95% CI: 7.36–14.7) and 8.49 (95% CI: 4.96–
11.5) months among patients receiving induction with VMP and
VTP, respectively (Fig. 2A). According to maintenance therapy, PFS
was 8.5 and 8.9 months among patients receiving VP or VT and
8.7 months in those patients who did not receive maintenance (P
non signiﬁcant). Median PFS was, 11.73 (95% CI: 4.24–17), 8.84
(95% CI: 6.18–15.3), and 7.90 (95% CI: 3.15–12.5) for patients re-
ceiving bortezomib-, lenalidomide-, and chemotherapy-based
therapies at time of relapse, respectively (Fig. 2B). No signiﬁcant
differences were observed in PFS among patients in the VMP and
VTP groups according to the type of therapy administered at re-
lapse (data not shown).
3.7. Overall survival
At the time of analysis, 108 (74.4%) patients have died, includ-
ing 44 (65.6%) and 64 (82%) in the VMP and VTP arms, respectively.
Median OS from start of subsequent therapy in the overall series of
patients was 17 months (95% IC: 13.8–22.4). OS from time of re-
lapse was signiﬁcantly longer among patients receiving front-line
therapy with VMP, 21.4 (95% IC: 13.8–36.4) months when com-
pared with those in the VTP group, 14.4 (95% IC: 11.9–21.7) months
(P¼ 0.037; Fig. 3). Likewise, OS was also signiﬁcantly longer
among patients achieving CR after relapse when compared with
patients who did not achieve CR (28.3 vs. 14.8 months; P¼0.04)
(Fig. 4).
When the type of relapse was considered, median OS was, re-
spectively 28.6 (95% CI: 14–43), 18.1 (95% CI: 15–25), and 7.6 (95%
CI: 5–18) months after asymptomatic, clinical, and aggressive re-
lapse (P¼0.0007) (Fig. 5). Finally, no differences in OS wereobserved according to the type of treatment administered at re-
lapse or depending on the type of maintenance therapy adminis-
tered (data not shown).4. Discussion
In our study, including 145 elderly patients with MM in ﬁrst
relapse after front-line treatment including new drugs, both the
type of relapse and the achievement of CR post relapse were the
main factors affecting outcome, while the type of regimen ad-
ministered to treat relapse had a minor impact on post relapse
evolvement.
Fig. 3. Overall survival according to front-line treatment.
Fig. 4. Overall survival according to the type of response achieved after relapse.
Fig. 5. Overall survival according to the type of relapse.
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bortezomib as part of the GEM2005MAS65 trial and 50% of them
also received thalidomide during the induction regimen. It has
been hypothesized that by the exposure to novel agents in re-
lapsed or refractory multiple MM, more resistant subclones may
survive under the selective stress of the agents, explaining the
more aggressive forms of relapse [14]. Our ﬁndings, however, do
not support this hypothesis. In fact, an asymptomatic increase in
the monoclonal component along with the reappearance of the
classical CRAB symptoms were the most commonly forms of re-
lapse (113 patients, 78%) and only 32 (22%) patients developedaggressive relapse. This pattern of relapse is similar to that ob-
served in younger patients who received induction with conven-
tional chemotherapy followed by autologous transplantation [6–
8]. Thus, the type of relapse might be more related with disease
biology such as the intraclonal heterogeneity recently reported in
MM [15,16]. However, additional studies are needed to try to
clarify whether exposure to regimens including one or more novel
drugs during induction will increase the risk of more resistant
disease at time of relapse.
The overall and CR rate after relapse were 51.7% and 11%, re-
spectively and not inﬂuenced by the type of regimen administered in
the front-line therapy (VMP or VTP). However, achievement of CR
after relapse was associated to a signiﬁcantly longer OS when com-
pared with those patients who obtained less than CR (28.3 vs. 14.8
months; P¼0.04). In newly diagnosed MM patients an association
between achieving deep levels of remission and long-term survival
has been proved conﬁrming this parameter as a valid surrogate
marker of the treatment efﬁcacy [18] but the value of the depth of
response in the relapse setting has been less investigated [19]. Our
results, however strongly suggest that CR should also be a valid ob-
jective of any therapeutic strategy even in patients in relapse.
Median PFS after ﬁrst relapse in the overall series was 8.84
months with no differences between VMP and VTP and shorter
than the corresponding ﬁgure observed with the use of lenalido-
mide and dexamethasone in ﬁrst relapse by other groups [17].
However, it must be noted that these results were achieved at a
time when novel agents were rarely used upfront, and results
might be different in patients who received novel agents as ﬁrst-
line treatment like those included in our study. Although direct
comparisons are not possible, the PFS observed in our study was
similar to that recently reported with bortezomib and dex-
amethasone [20] but shorter than that observed with different
three-drug regimens such as bortezomib, dexamethasone, and
panobinostat [20] or lenalidomide, dexamethasone, and carﬁlzo-
mib [21] suggesting that a triple combination may be more ef-
fective for this subgroup of patients. However, it should also be
highlighted that median age at time of relapse was much higher in
our series than in other studies dealing with MM patients in re-
lapse a fact that also may explain the shorter duration of PFS ob-
served in our study [14,17,20,21].
In MM, the optimal sequence or combination of the different
therapeutic regimens available remains unclear and information is
needed on the efﬁcacy of each treatment after various prior
therapies. Although a substantial number of different regimens
and schedules were used for the treatment of ﬁrst relapse, lena-
lidomide-based were the most commonly used combinations for
treatment at relapse (53.8% of patients) and 17.3% were retreated
with bortezomib at time of relapse. The overall response rate was
higher among patients receiving rescue therapy with lenalidomide
when compared with bortezomib combinations (67% and 44%,
respectively; P¼0.04) but similar CR rate in both groups of pa-
tients. Interestingly, no differences in PFS were observed among
both groups of patients despite the fact that every patient had
been previously exposed to bortezomib. These ﬁndings suggest
that, retreatment with the same class of drugs on which patients
have previously responded may be effective and represents a
feasible and effective treatment option for patients with relapsed
MM who previously responded to these drugs and a potential al-
ternative to initiating subsequent line therapy with a different
class of agents.
In our study, OS after relapse was also signiﬁcantly prolonged
in those patients receiving front-line therapy with VMP, conﬁrm-
ing the superiority of this regimen when compared with VTP, a
ﬁnding previously reported for the whole series of patients [11].
As expected, our results showed a signiﬁcantly shorter
OS among patients with more aggressive forms of relapse (7.6
A. Lopez et al. / Leukemia Research Reports 4 (2015) 64–69 69months) when compared with those patients presenting clinical
(18.1 months) or biological (28.6 months) relapse suggesting that
alternative, more efﬁcacious rescue therapies are clearly needed in
this subgroup of patients.
It is well-recognized that relapse can take different forms, and
several groups have described various relapse patterns. However,
the majority of these reports focused on patients relapsing after
conventional chemotherapy or autologous stem cell transplanta-
tion and data about relapse patterns in elderly patients receiving
front-line treatment with new drugs are limited [6,7]. Our results,
however, showed a signiﬁcantly shorter OS among patients with
more aggressive forms of relapse (7.6 months) when compared
with those patients presenting clinical (18.1 months) or biological
(28.6 months) relapse suggesting the utility of these classiﬁcations
and that alternative, more efﬁcacious rescue therapies are clearly
needed for these subgroups of patients.
This study has some limitations. We investigated only the type
of regimen administered at relapse and no data about doses or
schedule of the drugs used were available. In this regard, hetero-
geneity of the ageing process is characterized by marked varia-
bility in the rate of functional deterioration, both between and
within individuals. Therefore, individualized management, tai-
lored to differences in functional capacity, life expectancy, and
social and economic support, is needed to better deﬁne and op-
timal treatment strategy for these patients [22,23].
In conclusion, our study shows that patterns of relapse in el-
derly patients receiving front line therapy including novel agents
are similar to that observed after conventional chemotherapy with
patients with more aggressive forms of relapse doing poorly. Our
results also show that PFS after relapse is similar regardless the
induction regimen (VMP or VTP) administered at diagnosis and
the type of treatments administered at relapse. Finally, a sig-
niﬁcantly longer post relapse OS was observed among patients
receiving VMP at induction and in the subgroup of patients
achieving CR after relapse.Authors contributions
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